Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the limited number of approved agents. Patients with MASH are at risk of liver fibrosis, cardiovascular disease, and cancer. In 2024, the FDA approved the first-ever drug for MASH: resmetirom (Rezdiffra). Guidelines recommend the use of available therapies for the management of comorbidities associated with MASH. Consequently, there is a pressing need for new, effective MASH-specific drug treatments. In this report, hepatologists and gastroenterologists reveal which attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future MASH treatments. Using the Target Product Profile (TPP) Simulator, we can establish physicians’ preferences for emerging drugs and assess if these drugs can capitalize on this untapped space.
Questions answered
- How do hepatologists and gastroenterologists rate current MASH treatment options such as resmetirom, pioglitazone, and GLP-1 RA products?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and price are needed from new MASH drugs to be preferred over current treatment options?
- What are the areas of greatest unmet need and opportunity in MASH?
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 32 European medical oncologists
Key drugs covered: Resmetirom, GLP-1 RA products, vitamin E, pioglitazone
Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
